Roger McIntyre
Professor of Psychiatry and Pharmacology at the University of Toronto
Key Impact
A global leader in mood disorder research and a pioneer in rapid-acting treatments like ketamine.
Background & Research
Roger McIntyre is one of the world's most cited researchers in the field of depression and bipolar disorder. Head of the Mood Disorders Psychopharmacology Unit at UHN, he has been instrumental in the clinical implementation of ketamine for treatment-resistant depression. He leads multiple international initiatives to improve brain health and psychiatric care through innovative pharmacological and psychedelic research.
Collaboration Network
38 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Depressive DisordersMajor Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)SuicidalityAnxiety DisordersBipolar DisorderSafety & Risk ManagementChronic PainSchizophreniaHeadache Disorders (Cluster & Migraine)Palliative & End-of-Life DistressAdolescentsPublic Health, Prevention & Behaviour ChangeSubstance Use Disorders (SUD)Personality DisordersNeurocognitive DisordersHealthy VolunteersMedicinal Chemistry & Drug DevelopmentAlcohol Use Disorder (AUD)Neuroimaging & Brain MeasuresBorderline Personality Disorder (BPD)PTSDEquity and EthicsOlder AdultsHealth Economics & ReimbursementImmunology & InflammationObsessive-Compulsive Disorder (OCD)